Virginia Commonwealth University

The Children's Hospital of Philadelphia

King Abdulaziz University

Mohini Ghatge

Martin K Safo

Yan Zhang

Osheiza Abdulmalik

Jurgen Venitz

Kevin R Ward

Richmond E Danso-Danquah

Martin J Mangino

Moustafa El-Sayed El-Araby

Guoyan Xu

Abdelsattar Mansour Ebid Omar

Piyusha Pradeep Pagare

Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).

Aromatic aldehydes with sustained and enhanced in vitro and in vivo pharmacologic activity to treat sickle cell disease

Azolylacryloyl derivatives with hypoxic properties are provided. The compounds have a generic formula: and are suitable for treating sickle cell disease and hypoxia-underlying diseases, e.g. hemorrhagic and traumatic shock, cardiac arrest and cardiogenic shock, traumatic brain injury, cancer, stroke, myocardial infarction, myocardial ischemia, vaso-occlusive crisis, etc. 

Azolylacryloyl derivatives as therapeutic agents for sickle cell disease

Allosteric hemoglobin (Hb) modifiers of hemoglobin which contain nitric oxide (NO) moieties allowing for the release of NO in vivo. The compounds retain the oxygen delivery capability of the allosteric hemoglobin modifier to bind Hb and enhance Hb's ability to deliver oxygen to cells and tissues, and also release NO from the NO moiety. Methods of delivering oxygen and/or NO to cells and tissues are also provided.

Allosteric hemoglobin modifiers with nitric oxide releasing moiety

Growing community of inventors

Glen Allen, VA, United States of America

Mohini Ghatge